• Personalis disclosed a new Medicare coverage determination that expands use of its NeXT Personal blood-based MRD test to monitor response to pre-surgical treatment in Stage II-III triple-negative or HER2-positive breast cancer.
• The clinical evidence supporting the move was already published from the prospective PREDICT-DNA study in the Journal of Clinical Oncology.
• Study findings indicated the test can track treatment response during neoadjuvant therapy and better anticipate longer-term outcomes than standard clinical assessments.
• The expanded reimbursement broadens the product’s addressable breast cancer use beyond post-surgery surveillance into active treatment management, a shift that can support higher utilization in eligible Medicare patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605200600BIZWIRE_USPR_____20260520_BW448802) on May 20, 2026, and is solely responsible for the information contained therein.